Tao Wu

机构：Central South University, Nanchang University, Shanxi Medical University, Qinghai University Affiliated Hospital, Second Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Xi'an Jiaotong University, Tang Du Hospital, Shanxi Provincial People’s Hospital, Air Force Medical University · ORCID：0000-0003-2725-8442

发表论文 136 篇 · 总被引 1499 次 · h-index 20

代表论文

• Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial (2025 · Molecular Cancer · 被引 10)
• Effect of body mass index on postoperative lymphedema after breast cancer: a systematic review and meta-analysis (2025 · Discover Oncology · 被引 5)
• Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study (2025 · The Oncologist · 被引 4)
• Cadonilimab plus platinum-based chemotherapy ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of COMPASSION-16. (2025 · Journal of Clinical Oncology · 被引 3)
• TNMpBC-NeoBCSS model: a breast cancer specific survival prediction model for triple-negative metaplastic breast carcinoma patients with neoadjuvant therapy (2025 · Scientific Reports · 被引 3)
• Impact of HER2-ultralow heterogeneity and optimal threshold on trastuzumab deruxtecan (T-DXd) efficacy in metastatic breast cancer: A national multicenter cohort study (HEROIC). (2025 · Journal of Clinical Oncology · 被引 1)